Literature DB >> 16622021

Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen.

Luis E Perez1, Bysani Chandrasekar, Omar A Saldarriaga, Weiguo Zhao, Lourdes T Arteaga, Bruno L Travi, Peter C Melby.   

Abstract

Progressive disease in the hamster model of visceral leishmaniasis, caused by Leishmania donovani, in contrast to infection in mice, mimics the progressive disease observed in untreated humans. During progressive infection in hamsters, there was a vigorous type 1 cellular immune response, which is typically associated with control of infection, suggesting that there was ineffective IFN-gamma-mediated macrophage activation. Indeed, at the site of infection, hamsters did not express NO synthase 2 (NOS2), which is the primary mechanism for control of infection in mice. Furthermore, in striking contrast to mouse macrophages, IFN-gamma-activated hamster macrophages did not did not express NOS2 nor generate NO, and were unable to restrict the replication of intracellular L. donovani. The absent hamster NOS2 expression was not the result of NOS2 gene deletion and the NOS2 cDNA had an intact open reading frame. Furthermore, the impaired transcription of NOS2 mRNA was selective and not due to global impairment of IFN-gamma signaling (members of the IFN-gamma-signaling pathway were expressed and functional and IFN-gamma up-regulated several primary and secondary response genes). Strikingly, the proximal hamster NOS2 promoter, like the human ortholog, had >20-fold less basal and IFN-gamma/LPS-inducible activity than the corresponding mouse promoter. Thus, reduced basal and IFN-gamma-induced activity of the hamster NOS2 transcriptional unit, which is unique to this small animal and similar to the human counterpart, accompanies the inability of the animal to control an intracellular pathogen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622021     DOI: 10.4049/jimmunol.176.9.5519

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Role for nitric oxide in hookworm-associated immune suppression.

Authors:  Blaise Dondji; Richard D Bungiro; Lisa M Harrison; Jon J Vermeire; Carlo Bifulco; Diane McMahon-Pratt; Michael Cappello
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

Review 2.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

3.  Identification of hamster inducible nitric oxide synthase (iNOS) promoter sequences that influence basal and inducible iNOS expression.

Authors:  Omar A Saldarriaga; Bruno L Travi; Goutam Ghosh Choudhury; Peter C Melby
Journal:  J Leukoc Biol       Date:  2012-04-18       Impact factor: 4.962

4.  Comparative evaluation of lesion development, tissue damage, and cytokine expression in golden hamsters (Mesocricetus auratus) infected by inocula with different Leishmania (Viannia) braziliensis concentrations.

Authors:  Raquel P Ribeiro-Romão; Otacílio C Moreira; Elvia Yaneth Osorio; Lea Cysne-Finkelstein; Adriano Gomes-Silva; Joanna G Valverde; Claude Pirmez; Alda Maria Da-Cruz; Eduardo Fonseca Pinto
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

Review 5.  The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist.

Authors:  Peter E Kima
Journal:  Int J Parasitol       Date:  2007-04-29       Impact factor: 3.981

6.  Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.

Authors:  Felicitat Todolí; Alhelí Rodríguez-Cortés; María Del Carmen Núñez; Márcia D Laurenti; Silvia Gómez-Sebastián; Fernando Rodríguez; Eva Pérez-Martín; José M Escribano; Jordi Alberola
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

7.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

8.  Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.

Authors:  E Yaneth Osorio; Weiguo Zhao; Claudia Espitia; Omar Saldarriaga; Leo Hawel; Craig V Byus; Bruno L Travi; Peter C Melby
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

9.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

10.  Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.

Authors:  Yan-Gao Man; Alexander Stojadinovic; Jeffrey Mason; Itzhak Avital; Anton Bilchik; Bjoern Bruecher; Mladjan Protic; Aviram Nissan; Mina Izadjoo; Xichen Zhang; Anahid Jewett
Journal:  J Cancer       Date:  2013-01-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.